HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

HeartBeam Inc. (NASDAQ: BEAT) announced that a peer-reviewed article published in JACC: Advances has validated the use of its portable ECG device for identifying heart attack risk. The study, a proof-of-concept analysis involving 184 patients, found that a risk prediction algorithm incorporating a single HeartBeam ECG reading along with patient risk factors and symptoms achieved an area under the curve (AUC) of 86.5%. This accuracy increased to 92.9% when a personal, symptom-free baseline ECG was available for comparison.

The results support heart attack detection as a future indication for the HeartBeam System, advancing the company's broader clinical program. HeartBeam's technology is designed for portable devices that can collect ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. This platform aims to deliver actionable cardiac insights outside of medical facilities, potentially transforming cardiac care by enabling early detection and timely intervention.

The company highlighted that the algorithm's high AUC values indicate strong predictive power, suggesting that the HeartBeam device could be a valuable tool for emergency departments and primary care settings to quickly rule out or confirm heart attacks. The study's findings are particularly significant given that chest pain is one of the most common reasons for emergency visits, and accurate risk stratification can reduce unnecessary hospitalizations and improve patient outcomes.

HeartBeam's 3D ECG technology has already received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. For more information about the study, the full press release is available at https://ibn.fm/ainxV. Additional updates on BEAT can be found in the company's newsroom at https://ibn.fm/BEAT.

The implications of this study are far-reaching. If HeartBeam can secure clearance for heart attack detection, it could provide a reliable, portable, and cost-effective alternative to traditional 12-lead ECGs, which are often not available in ambulatory or remote settings. This would empower physicians to identify cardiac health trends and acute conditions, directing patients to appropriate care more efficiently. The ability to use a personal baseline ECG for comparison further enhances accuracy, as it accounts for individual variations in heart electrical activity.

HeartBeam's approach addresses a critical gap in cardiac care: the need for continuous monitoring and early detection of life-threatening events. With the aging population and rising prevalence of cardiovascular diseases, such innovations are crucial. The study published in JACC: Advances, a leading cardiology journal, adds credibility to the technology and may accelerate adoption among clinicians.

For investors, this development signals HeartBeam's progress toward expanding its product indications, which could open up a significant market opportunity. The company's focus on transforming cardiac care through portable, intelligent devices aligns with the broader trend toward decentralized healthcare. As HeartBeam continues to gather clinical evidence, it moves closer to realizing its vision of delivering actionable heart intelligence wherever the patient is.